Marta Nyakas
Overview
Explore the profile of Marta Nyakas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ascierto P, Tang H, Dolfi S, Nyakas M, Marie Svane I, Munoz-Couselo E, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 40010775
Background: Some patients with melanoma experience disease progression during immunotherapy (IO) and may benefit from novel combinations of immune checkpoint inhibitors (ICIs). We report results from exploratory biomarker analyses to...
2.
Long G, Hauschild A, Santinami M, Kirkwood J, Atkinson V, Mandala M, et al.
N Engl J Med
. 2024 Jun;
391(18):1709-1720.
PMID: 38899716
Background: The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis-free survival than placebo among patients with V600-mutated...
3.
Robert C, Carlino M, McNeil C, Ribas A, Grob J, Schachter J, et al.
J Clin Oncol
. 2023 Jun;
41(24):3998-4003.
PMID: 37348035
JCO Immune checkpoint inhibitors have led to unprecedented prolongation of overall survival (OS) for patients with advanced melanoma. Five-year follow-up of KEYNOTE-006 showed pembrolizumab prolonged survival versus ipilimumab. Efficacy results...
4.
Winge-Main A, Robsahm T, Nyakas M, Festervoll G, Torkilseng E, Thybo S, et al.
Future Oncol
. 2023 Mar;
19(3):205-215.
PMID: 36974621
This study was performed to investigate the characteristics and overall survival (OS) of patients with completely resected stage IIB-IV cutaneous melanoma identified in the Cancer Registry of Norway. A retrospective...
5.
Ascierto P, Lipson E, Dummer R, Larkin J, Long G, Sanborn R, et al.
J Clin Oncol
. 2023 Feb;
41(15):2724-2735.
PMID: 36780608
Purpose: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved progression-free survival (PFS) for...
6.
Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O, et al.
J Clin Invest
. 2023 Jan;
133(6).
PMID: 36719749
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on...
7.
Shoushtari A, Olszanski A, Nyakas M, Hornyak T, Wolchok J, Levitsky V, et al.
Clin Cancer Res
. 2022 Sep;
29(1):100-109.
PMID: 36112545
Purpose: Intratumoral oncolytic virotherapy may overcome anti-PD(L)-1 resistance by triggering pro-inflammatory remodeling of the tumor microenvironment. This pilot study investigated ONCOS-102 (oncolytic adenovirus expressing GM-CSF) plus anti-programmed cell death protein...
8.
Nyakas M, Fleten K, Haugen M, Engedal N, Sveen C, Farstad I, et al.
Sci Rep
. 2022 Mar;
12(1):5076.
PMID: 35332208
More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to...
9.
Ragnum H, De Bortoli A, Elsais A, Nilsen K, Hammarstrom C, Nyakas M
Tidsskr Nor Laegeforen
. 2021 Sep;
141(2021-12).
PMID: 34505469
No abstract available.
10.
Aamdal E, Jacobsen K, Straume O, Kersten C, Herlofsen O, Karlsen J, et al.
Int J Cancer
. 2021 Aug;
150(1):100-111.
PMID: 34449877
Ipilimumab was the first treatment that improved survival in advanced melanoma. Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and...